{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:09:59Z","timestamp":1778170199941,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015135","name":"Haemonetics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015135","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Albert-Ludwigs-Universit\u00e4t Freiburg im Breisgau"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of hemostatic markers might help identify patients at increased risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To identify hemostatic markers associated with MACE and bleeding following TAVR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this prospective single-center cohort study, of patients undergoing TAVR from November 2020 to June 2022, the association of hemostatic profiles and clinical outcomes was assessed. The profiling included thromboelastography (TEG), light transmission aggregometry (LTA), and conventional laboratory markers to assess thrombogenicity. The outcome was MACE (death, myocardial infarction, or stroke) and major\/non-major clinically relevant bleeding at 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 107 patients included, 104 completed follow-up. At 6 months, 9% experienced MACE, and 10% had clinically relevant bleeding. Platelet\u2013fibrin clot strength, reflected by the maximum amplitude (MA-citrated kaolin) in thrombelastography, was elevated in patients with MACE (per 1 mm increase: HR 1.26 [1.02;1.56], <jats:italic>p<\/jats:italic>\u2009=\u20090.03). Fibrin\u2019s role in the maximum clot strength was crucial. Elevated fibrinogen levels, increased citrated functional fibrinogen (MA-CFF), and faster fibrin formation (alpha-angle[\u03b1]) associated with a higher risk of MACE (per 20 mg\/dL fibrinogen increase: HR 1.15 [1.02\u20131.28], <jats:italic>p<\/jats:italic>\u2009=\u20090.02; per 5 mm MA-CFF increase: HR 1.59 [1.12\u20132.26], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01; per degree \u03b1-citrated rapid TEG increase: HR 1.55 [1.10\u20132.19], <jats:italic>p<\/jats:italic>\u2009=\u20090.01), respectively. High on-treatment ADP-induced platelet reactivity assessed by LTA was associated with a lower risk of major and non-major clinically relevant bleeding at 6 months (per 10% MA-ADP increase:   HR 0.66 [0.47;0.93]\ufeff <jats:italic>p=0.02<\/jats:italic> \ufeff\ufeff).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Selected hemostatic markers associated with the risk of MACE and bleeding within 6 months in patients post-TAVR, with fibrin clot strength identified as a principal marker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00392-025-02749-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:03:29Z","timestamp":1759759409000},"page":"1606-1615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR"],"prefix":"10.1007","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-262X","authenticated-orcid":false,"given":"David","family":"Hesselbarth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"D\u2019Orazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Ciccarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diona","family":"Gjermeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"J\u00fclch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Wessinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariya","family":"Maslarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rilinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Pottgiesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"von zur M\u00fchlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph B.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"4","key":"2749_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.acvd.2019.12.003","volume":"113","author":"A Trimaille","year":"2020","unstructured":"Trimaille A, Marchandot B, Park SH, Schini-Kerth V, Morel O (2020) The difficult balance between thrombosis and bleeding after transcatheter aortic valve replacement: a translational review. Arch Cardiovasc Dis 113(4):263\u2013275. https:\/\/doi.org\/10.1016\/j.acvd.2019.12.003","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"2749_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100761","volume":"3","author":"S Hecht","year":"2024","unstructured":"Hecht S, Giuliani C, Nuche J et al (2024) Multimarker approach to improve risk stratification of patients undergoing transcatheter aortic valve implantation. JACC: Advances 3(2):100761. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100761","journal-title":"JACC: Advances"},{"issue":"29","key":"2749_CR3","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","volume":"43","author":"JP Collet","year":"2022","unstructured":"Collet JP, Van Belle E, Thiele H et al (2022) Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 43(29):2783\u20132797. https:\/\/doi.org\/10.1093\/eurheartj\/ehac242","journal-title":"Eur Heart J"},{"issue":"2","key":"2749_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, W\u00f6hrle J et al (2020) A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 382(2):120\u2013129. https:\/\/doi.org\/10.1056\/NEJMoa1911425","journal-title":"N Engl J Med"},{"issue":"2","key":"2749_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","volume":"160","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Navickas IA et al (2010) Adenosine diphosphate\u2013induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 160(2):346\u2013354. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.034","journal-title":"Am Heart J"},{"issue":"19","key":"2749_CR6","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","volume":"44","author":"SH Lee","year":"2023","unstructured":"Lee SH, Kim HK, Ahn JH et al (2023) Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J 44(19):1718\u20131728. https:\/\/doi.org\/10.1093\/eurheartj\/ehad088","journal-title":"Eur Heart J"},{"issue":"4","key":"2749_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.5858\/arpa.2016-0088-OA","volume":"141","author":"JD Dias","year":"2017","unstructured":"Dias JD, Haney EI, Mathew BA, Lopez-Espina CG, Orr AW, Popovsky MA (2017) New-generation thromboelastography: comprehensive evaluation of citrated and heparinized blood sample storage effect on clot-forming variables. Arch Pathol Lab Med 141(4):569\u2013577. https:\/\/doi.org\/10.5858\/arpa.2016-0088-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"2749_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","volume":"42","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"VARC-3 WRITING COMMITTEE, G\u00e9n\u00e9reux P, Piazza N et al (2021) Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J 42(19):1825\u20131857. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa799","journal-title":"Eur Heart J"},{"issue":"28","key":"2749_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/eurheartj\/ehv756","volume":"37","author":"R Puri","year":"2016","unstructured":"Puri R, Iung B, Cohen DJ, Rod\u00e9s-Cabau J (2016) TAVI or no TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J 37(28):2217\u20132225. https:\/\/doi.org\/10.1093\/eurheartj\/ehv756","journal-title":"Eur Heart J"},{"key":"2749_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00031","volume":"5","author":"C Oury","year":"2018","unstructured":"Oury C, Nchimi A, Lancellotti P, Bergler-Klein J (2018) Can blood biomarkers help predicting outcome in transcatheter aortic valve implantation? Front Cardiovasc Med 5:31. https:\/\/doi.org\/10.3389\/fcvm.2018.00031","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2749_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002132","volume":"9","author":"M Harada","year":"2022","unstructured":"Harada M, Sajima T, Onimaru T et al (2022) Changes in platelet function and coagulation after transcatheter aortic valve implantation evaluated with thromboelastography. Open Heart 9(2):e002132. https:\/\/doi.org\/10.1136\/openhrt-2022-002132","journal-title":"Open Heart"},{"issue":"25","key":"2749_CR12","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/eurheartj\/ehae296","volume":"45","author":"O Kwon","year":"2024","unstructured":"Kwon O, Ahn JH, Koh JS et al (2024) Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J 45(25):2217\u20132231. https:\/\/doi.org\/10.1093\/eurheartj\/ehae296","journal-title":"Eur Heart J"},{"issue":"9","key":"2749_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","volume":"258","author":"WB Kannel","year":"1987","unstructured":"Kannel WB (1987) Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 258(9):1183. https:\/\/doi.org\/10.1001\/jama.1987.03400090067035","journal-title":"JAMA"},{"issue":"1","key":"2749_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00610-x","volume":"22","author":"D Gjermeni","year":"2024","unstructured":"Gjermeni D, Anfang V, Szab\u00f3 S et al (2024) D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention. Thromb J 22(1):42. https:\/\/doi.org\/10.1186\/s12959-024-00610-x","journal-title":"Thromb J"},{"key":"2749_CR15","doi-asserted-by":"publisher","unstructured":"Tantry US, Bliden KP, Ashley WW, Gurbel PA (2024) New interest in fibrinogen as an ischemic risk factor. J Thromb Thrombolysis. Published online August 7, 2024https:\/\/doi.org\/10.1007\/s11239-024-03024-8","DOI":"10.1007\/s11239-024-03024-8"},{"key":"2749_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.amjcard.2021.01.042","volume":"147","author":"T Katayama","year":"2021","unstructured":"Katayama T, Yokoyama N, Watanabe Y et al (2021) Blood coagulation changes with or without direct oral anticoagulant therapy following transcatheter aortic valve implantation. Am J Cardiol 147:88\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2021.01.042","journal-title":"Am J Cardiol"},{"key":"2749_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijcard.2022.01.072","volume":"352","author":"G Tirado-Conte","year":"2022","unstructured":"Tirado-Conte G, Salazar CH, McInerney A et al (2022) Incidence, clinical impact and predictors of thrombocytopenia after transcatheter aortic valve replacement. Int J Cardiol 352:21\u201326. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.072","journal-title":"Int J Cardiol"},{"key":"2749_CR18","doi-asserted-by":"publisher","unstructured":"Guthoff H, Lohner V, Mons U, et al. (2025) Evaluation of systemic inflammatory response following transcatheter aortic valve replacement: a pathway to rational antibiotic use. Infection. Published online February 7, 2025. https:\/\/doi.org\/10.1007\/s15010-025-02485-0","DOI":"10.1007\/s15010-025-02485-0"},{"issue":"18","key":"2749_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","volume":"382","author":"VJ Nijenhuis","year":"2020","unstructured":"Nijenhuis VJ, Brouwer J, Delewi R et al (2020) Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 382(18):1696\u20131707. https:\/\/doi.org\/10.1056\/NEJMoa1915152","journal-title":"N Engl J Med"},{"key":"2749_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jocn.2020.06.004","volume":"78","author":"T Shao","year":"2020","unstructured":"Shao T, Cheng Y, Jin J et al (2020) A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy. J Clin Neurosci 78:91\u201396. https:\/\/doi.org\/10.1016\/j.jocn.2020.06.004","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2749_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejvs.2018.06.032","volume":"56","author":"E Grifoni","year":"2018","unstructured":"Grifoni E, Gori AM, Giusti B et al (2018) On-treatment platelet reactivity is a predictor of adverse events in peripheral artery disease patients undergoing percutaneous angioplasty. Eur J Vasc Endovasc Surg 56(4):545\u2013552. https:\/\/doi.org\/10.1016\/j.ejvs.2018.06.032","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"16","key":"2749_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D et al (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12(16):1521\u20131537. https:\/\/doi.org\/10.1016\/j.jcin.2019.03.034","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"2749_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11239-023-02937-0","volume":"57","author":"D Gjermeni","year":"2024","unstructured":"Gjermeni D, Anfang V, Vetter H et al (2024) Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study. J Thromb Thrombolysis 57(3):361\u2013369. https:\/\/doi.org\/10.1007\/s11239-023-02937-0","journal-title":"J Thromb Thrombolysis"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02749-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:04:21Z","timestamp":1761048261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02749-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02749-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CBO received research support from Bundesministerium f\u00fcr Bildung und Forschung,\u00a0Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, University of Freiburg, Else Kr\u00f6ner-Fresenius Stiftung, and Haemonetics; Honoraria: Bayer Vital GmbH, BMS, B\u00f6hringer Ingelheim, Daiichi Sankyo, Ferrer, Idorsia, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}